Alpine Global Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Alpine Global Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $89,632 - $176,659	-52,112 Reduced 20.84%	197,888 $584,000
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $807,500 - $1.15 Million	250,000 New	250,000 $845,000
Q1 2021 May 13, 2021	SELL	$4.23 - $6.55 $107,183 - $165,970	-25,339 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$5.73 - $9.03 $145,192 - $228,811	25,339 New	25,339 $145,000
Q2 2018 Aug 15, 2018	SELL	$10.66 - $14.38 $159,185 - $214,736	-14,933 Closed	0 $0
Q1 2018 May 16, 2018	SELL	$9.0 - $15.16 $169,776 - $285,978	-18,864 Reduced 55.82%	14,933 $194,000
Q4 2017 Feb 14, 2018	BUY	$7.67 - $9.31 $259,222 - $314,650	33,797	33,797 $311,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Alpine Global Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpine Global Management, LLC with notifications on news.